Univercells secures up to €50M investment from KKR platform to speed delivery of manufacturing technologies

February 18th 2020


Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced biologic therapies including gene- and cell-based therapies.  Please discover the press release here.